Market Place
Sourcing Support
Taiho Oncology to Present Data at 66th ASH 2024
05 Nov 2024 //
PR NEWSWIRE
Taiho Announces Publication of Final Results of Phase 3 of Decitabine and Cedazuridine
23 Jan 2024 //
PR NEWSWIRE
Taiho Announces Presentation of Data of Oral Decitabine and Cedazuridine
10 Dec 2023 //
PR NEWSWIRE
Otsuka and Astex announce that the European Commission has approved INAQOVI
19 Sep 2023 //
BUSINESSWIRE
EMA accepts application for leukaemia drug from Otsuka and Astex
23 Aug 2022 //
PHARMATIMES
EMA begin Review of Oral Fixed-Dose Combination of Decitabine & Cedazuridine
22 Aug 2022 //
BUSINESSWIRE
EC Grants ODD to Oral Decitabine and Cedazuridine in AML
05 Jan 2022 //
BUSINESSWIRE
Astex Presents OS Data From Phase 3 of INQOVI in MDS and CMML
23 Sep 2021 //
BUSINESSWIRE
National Comprehensive Cancer Network® Adds INQOVI®
23 Nov 2020 //
PRNEWSWIRE
Astex Expands Clinical Evaluation of Oral Decitabine and Cedazuridine
28 Oct 2020 //
BIOSPACE
Astex`s Inqovi nod gives patients on decitabine a non-IV option
03 Aug 2020 //
FIERCE PHARMA
Inqovi, an Oral Therapy for Myelodysplastic Syndromes, Gets FDA Approval
13 Jul 2020 //
ONCOLOGYNURSEADIBISOR
Otsuka announcessimultaneous regulatory approvals U.SFDA & Health Canada INQOVI
08 Jul 2020 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.